Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03LJR
|
||||
| Former ID |
DAP000663
|
||||
| Drug Name |
Sirolimus
|
||||
| Synonyms |
Perceiva; RAP; RAPA; RPM; Rapammune; Rapamune; Rapamycin; Rapamycin Immunosuppressant Drug; Rapamycin from Streptomyces hygroscopicus; AY 22989; Antibiotic AY 22989; SIIA 9268A; SILA 9268A; Wy 090217; AY-22989; DE-109; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); WY-090217; Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; (-)-Rapamycin; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Immunosuppressive Agents
|
||||
| Company |
Wyeth
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C51H79NO13
|
||||
| InChI |
InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
|
||||
| InChIKey |
QFJCIRLUMZQUOT-HPLJOQBZSA-N
|
||||
| CAS Number |
CAS 53123-88-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
636884, 830671, 7890221, 7982025, 8145920, 11110132, 11110134, 11110139, 11528741, 12014635, 14816423, 14816426, 24430811, 24899339, 26701762, 26705530, 26705537, 26709840, 26713306, 37101833, 46391895, 46392864, 47289337, 48416541, 49635682, 49815675, 50103901, 50139515, 56310631, 56310880, 56311583, 56311585, 56311714, 56311827, 56311949, 56311983, 56312137, 56312183, 56312184, 56312185, 56312186, 56312645, 56312887, 56313330, 56313354, 56313375, 56313498, 56313803, 56313974, 56314022
|
||||
| ChEBI ID |
ChEBI:9168
|
||||
| SuperDrug ATC ID |
L04AA10
|
||||
| SuperDrug CAS ID |
cas=053123889
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Serine/threonine-protein kinase mTOR | Target Info | Inhibitor | [535660] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| HIF-1 signaling pathway | |||||
| mTOR signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| AMPK signaling pathway | |||||
| Insulin signaling pathway | |||||
| Thyroid hormone signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Glioma | |||||
| Prostate cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| Choline metabolism in cancer | |||||
| PANTHER Pathway | Hypoxia response via HIF activation | ||||
| Interleukin signaling pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||||
| IL12-mediated signaling events | |||||
| CDC42 signaling events | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| mTOR signaling pathway | |||||
| CXCR4-mediated signaling events | |||||
| EGFR-dependent Endothelin signaling events | |||||
| IL2 signaling events mediated by PI3K | |||||
| IFN-gamma pathway | |||||
| ErbB1 downstream signaling | |||||
| ErbB2/ErbB3 signaling events | |||||
| CXCR3-mediated signaling events | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| PathWhiz Pathway | Leucine Stimulation on Insulin Signaling | ||||
| WikiPathways | ErbB Signaling Pathway | ||||
| Senescence and Autophagy in Cancer | |||||
| Interferon type I signaling pathways | |||||
| Insulin Signaling | |||||
| EGF/EGFR Signaling Pathway | |||||
| Wnt Signaling Pathway Netpath | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Cardiac Hypertrophic Response | |||||
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||||
| PIP3 activates AKT signaling | |||||
| Polycystic Kidney Disease Pathway | |||||
| Alpha 6 Beta 4 signaling pathway | |||||
| BDNF signaling pathway | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| TSLP Signaling Pathway | |||||
| FSH signaling pathway | |||||
| Leptin signaling pathway | |||||
| TSH signaling pathway | |||||
| RANKL/RANK Signaling Pathway | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Integrated Breast Cancer Pathway | |||||
| SREBP signalling | |||||
| Signaling by Insulin receptor | |||||
| Costimulation by the CD28 family | |||||
| Type II diabetes mellitus | |||||
| MicroRNAs in cardiomyocyte hypertrophy | |||||
| TOR Signaling | |||||
| AMPK Signaling | |||||
| References | |||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 541290 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.